uniQure N.V. (0EE0.L)
USD 11.82
(0.0%)
USD 11.82
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -253.1 Million USD | -87.6% |
| 2022 | -108.01 Million USD | -142.15% |
| 2021 | 319 Million USD | 379.27% |
| 2020 | -126.97 Million USD | -2.63% |
| 2019 | -113.79 Million USD | -51.77% |
| 2018 | -74.01 Million USD | -14.61% |
| 2017 | -69.73 Million USD | 11.36% |
| 2016 | -63.96 Million USD | -27.02% |
| 2015 | -72.47 Million USD | -44.98% |
| 2014 | -45.71 Million USD | -26.12% |
| 2013 | -33.7 Million USD | -71.96% |
| 2012 | -18.09 Million USD | 15.89% |
| 2011 | -22.63 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -40.22 Million USD | 32.07% |
| 2024 Q1 | -52.73 Million USD | 8.03% |
| 2024 Q2 | -44.72 Million USD | 21.01% |
| 2023 Q3 | -81.87 Million USD | -38.17% |
| 2023 Q4 | -50.39 Million USD | 38.46% |
| 2023 FY | - USD | -87.6% |
| 2023 Q1 | -69.97 Million USD | -343.91% |
| 2023 Q2 | -59.25 Million USD | 15.32% |
| 2022 FY | - USD | -142.15% |
| 2022 Q2 | -56.06 Million USD | -9.44% |
| 2022 Q1 | -51.22 Million USD | -1448.35% |
| 2022 Q4 | 28.68 Million USD | 150.0% |
| 2022 Q3 | -57.37 Million USD | -2.35% |
| 2021 Q2 | 398 Million USD | 1035.26% |
| 2021 Q4 | 3.79 Million USD | 108.8% |
| 2021 Q3 | -43.17 Million USD | -110.85% |
| 2021 Q1 | -42.55 Million USD | -401.84% |
| 2021 FY | - USD | 379.27% |
| 2020 Q1 | -31.9 Million USD | -10.52% |
| 2020 Q3 | -44.49 Million USD | -23.02% |
| 2020 Q4 | -8.48 Million USD | 80.94% |
| 2020 FY | - USD | -2.63% |
| 2020 Q2 | -36.16 Million USD | -13.34% |
| 2019 Q3 | -26.97 Million USD | 2.15% |
| 2019 Q2 | -27.56 Million USD | -0.15% |
| 2019 Q1 | -27.52 Million USD | -31.27% |
| 2019 FY | - USD | -51.77% |
| 2019 Q4 | -28.87 Million USD | -7.05% |
| 2018 Q3 | -14.77 Million USD | 27.09% |
| 2018 Q1 | -17.09 Million USD | 19.85% |
| 2018 Q4 | -20.96 Million USD | -41.93% |
| 2018 FY | - USD | -14.61% |
| 2018 Q2 | -20.26 Million USD | -18.53% |
| 2017 Q4 | -21.32 Million USD | -184.88% |
| 2017 Q3 | -7.48 Million USD | 56.56% |
| 2017 Q2 | -17.23 Million USD | 3.62% |
| 2017 FY | - USD | 11.36% |
| 2017 Q1 | -17.88 Million USD | -44.42% |
| 2016 Q1 | -21.09 Million USD | -66.62% |
| 2016 FY | - USD | -27.02% |
| 2016 Q3 | -12.97 Million USD | 33.02% |
| 2016 Q2 | -19.37 Million USD | 8.16% |
| 2016 Q4 | -12.38 Million USD | 4.61% |
| 2015 FY | - USD | -44.98% |
| 2015 Q4 | -12.66 Million USD | -350.7% |
| 2015 Q1 | -8.43 Million USD | 10.38% |
| 2015 Q3 | -2.8 Million USD | 85.73% |
| 2015 Q2 | -19.68 Million USD | -133.32% |
| 2014 Q2 | -11.69 Million USD | -14.48% |
| 2014 Q3 | -9.27 Million USD | 20.63% |
| 2014 Q4 | -9.41 Million USD | -1.45% |
| 2014 FY | - USD | -26.12% |
| 2014 Q1 | -10.21 Million USD | 28.78% |
| 2013 Q1 | -6.31 Million USD | 2.25% |
| 2013 Q2 | -6.44 Million USD | -2.13% |
| 2013 Q3 | -7.06 Million USD | -9.51% |
| 2013 Q4 | -14.34 Million USD | -103.05% |
| 2013 FY | - USD | -71.96% |
| 2012 Q3 | -4.42 Million USD | 0.0% |
| 2012 FY | - USD | 15.89% |
| 2012 Q4 | -6.46 Million USD | -46.06% |
| 2011 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 181.57% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -187.663% |
| Myriad Genetics, Inc. | -67.8 Million USD | -273.304% |
| Evolus, Inc. | -41.81 Million USD | -505.358% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | -10.039% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 115.092% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 26.736% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -353.942% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 4.849% |
| bluebird bio, Inc. | -167.16 Million USD | -51.411% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -400.475% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | -10.95% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 333.651% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -174.873% |
| Dynavax Technologies Corporation | 9.66 Million USD | 2718.456% |
| Editas Medicine, Inc. | -163.11 Million USD | -55.165% |
| FibroGen, Inc. | -261.4 Million USD | 3.177% |
| Geron Corporation | -174.78 Million USD | -44.809% |
| Blueprint Medicines Corporation | -474.61 Million USD | 46.672% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 107.773% |
| Illumina, Inc. | -608 Million USD | 58.372% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 43.632% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -601.458% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 160.827% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -115.13% |
| Adicet Bio, Inc. | -136.53 Million USD | -85.374% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 42.372% |
| Insmed Incorporated | -654.73 Million USD | 61.343% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 50.011% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 121.743% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -578.862% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 357.577% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 97.756% |
| Waters Corporation | 1.02 Billion USD | 124.759% |
| Zoetis Inc. | 3.68 Billion USD | 106.868% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 102.344% |
| Biogen Inc. | 2.37 Billion USD | 110.648% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -189.499% |
| Nektar Therapeutics | -243.1 Million USD | -4.111% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -151.024% |
| Perrigo Company plc | 646.2 Million USD | 139.167% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | -12.493% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -143.853% |
| Verastem, Inc. | -83.16 Million USD | -204.331% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 105.496% |
| Imunon, Inc. | -20.78 Million USD | -1117.865% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -469.574% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | -68.612% |
| Homology Medicines, Inc. | -47.75 Million USD | -429.986% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 105.438% |
| OPKO Health, Inc. | -65.51 Million USD | -286.318% |
| Exelixis, Inc. | 196.6 Million USD | 228.737% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 156.002% |
| TG Therapeutics, Inc. | 26.1 Million USD | 1069.732% |
| Incyte Corporation | 919.42 Million USD | 127.528% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 49.911% |